Thera-SAbDab

OBINUTUZUMAB

>   Structural Summary
TherapeuticObinutuzumab
TargetMS4A1
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
Light ChainDIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
100% seqID Fv Structure3pp3 [Fvs: HL, IK], 3pp4 [Fvs: HL]
99% seqID Fv Structure6y9a [Fvs: HL]
95-98% seqID Fv Structure6y97 [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Obinutuzumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.57%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
obinutuzumab Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y A F S Y S W I N W V R Q A P G Q G L E W M G R I F P G D G D T D Y N G K F K G R V T I T A D K S T S T A Y M E L S S L R S E D T A V Y Y C A R N V F D G Y W L V Y W G Q G T L V T V S S
6y9a - V Q L V Q S G A E V K K P G S S V K V S C K A S G Y A F S Y S W I N W V R Q A P G Q G L E W M G R I F P G D G D T D Y N G K F K G R V T I T A D K S T S T A Y M E L S S L R S E D T A V Y Y C A R N V F D G Y W L V Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 30D 30E 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
obinutuzumab D I V M T Q T P L S L P V T P G E P A S I S C R S S K S L L H S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L V S G V P D R F S G S G S G T D F T L K I S R V E A E D V G V Y Y C A Q N L E L P Y T F G G G T K V E I K
6y9a D I V M T Q T P L S L P V T P G E P A S I S C R S S K S L L H S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L V S G V P D R F S G S G S G T D F T L K I S R V E A E D V G V Y Y C A Q N L E L P Y T F G G G T K V E I K
Sequence identity: 97.84%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
obinutuzumab Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y A F S Y S W I N W V R Q A P G Q G L E W M G R I F P G D G D T D Y N G K F K G R V T I T A D K S T S T A Y M E L S S L R S E D T A V Y Y C A R N V F D G Y W L V Y W G Q G T L V T V S S
6y97 - V Q L V Q S G A E V K K P G S S V K V S C K A S G Y A F S Y S W I N W V R Q A P G Q G L E W M G R I F P G D G D T D Y N G K F K G R V T I T A D K S T S T A Y M E L S S L R S E D T A V Y Y C A R N V F D G Y W L V Y W G Q G T L V T V - -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 30D 30E 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
obinutuzumab D I V M T Q T P L S L P V T P G E P A S I S C R S S K S L L H S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L V S G V P D R F S G S G S G T D F T L K I S R V E A E D V G V Y Y C A Q N L E L P Y T F G G G T K V E I K
6y97 D I V M T Q T P L S L P V T P G E P A S I S C R S S K S L L H S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L V S G V P D R F S G S G S G T D F T L K I S R V E A E D V G V Y Y C A Q N L E L P Y T F G G G T K V E - -
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyGlycoMAb Technology
INN Year Proposed2008
INN Year Recommended2011
Companies InvolvedGLYCART Biotechnology, Biogen Idec, Chugai Pharmaceutical, Dana-Farber Cancer Institute, Genentech, Lymphoma Academic Research Organisation, Nippon Shinyaku, OHSU Knight Cancer Institute, Pharmacyclics, Polish Myeloma Consortium, Roche, Thomas Jefferson University, University of Heidelberg, University of Leeds
Conditions ApprovedChronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin's lymphoma
Conditions ActiveDiffuse large B cell lymphoma, CNS cancer, Graft-versus-host disease, Lupus nephritis, Mantle-cell lymphoma, Waldenstrom's macroglobulinaemia
Conditions DiscontinuedPrimary biliary cirrhosis
NotesObinutuzumab is the new name for Afutuzumab (PL101)

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy